» Articles » PMID: 35528561

Impact of Soft Protein Interactions on the Excretion, Extent of Receptor Occupancy and Tumor Accumulation of Ultrasmall Metal Nanoparticles: a Compartmental Model Simulation

Overview
Journal RSC Adv
Specialty Chemistry
Date 2022 May 9
PMID 35528561
Authors
Affiliations
Soon will be listed here.
Abstract

Ultrasmall metal nanoparticles (NPs) are next-generation nano-based platforms for disease diagnosis and treatment. Due to their small size below the kidney filtration threshold and marked resistance to nonspecific serum protein adsorption, ultrasmall NPs can be rapidly excreted through the kidneys and escape liver uptake. However, although ultrasmall particles may be deemed highly resistant to protein adsorption, the real extent of this resistance is not known. Here, a simple compartmental model simulation was therefore implemented to understand how NP behavior could be modulated by soft, transient NP-plasma protein interactions characterized by dissociation constants in the millimolar range. In Model 1, ultrasmall NPs functionalized with a targeting probe, plasma proteins and target receptors were assumed to co-exist within a single compartment. Simulations were performed to understand the synergistic effect of soft interactions, systemic clearance and NP size on receptor occupancy in the single compartment. The results revealed the existence of a narrow range of ultraweak affinities and optimal particle sizes leading to greater target occupancy. In Model 2, simulations were performed to understand the impact of soft interactions on NP accumulation into a peripheral (tumor) compartment. The results revealed that soft interactions - but not active targeting - enhanced tumor uptake levels when tumor accumulation was limited by 'fast' plasma clearance and 'slow' vascular extravasation. The simple model presented here provides a basic framework to quantitatively understand the blood and tumor pharmacokinetics of ultrasmall NPs under the influence of transient protein interactions.

Citing Articles

Realizing active targeting in cancer nanomedicine with ultrasmall nanoparticles.

Lima A, Justo G, Sousa A Beilstein J Nanotechnol. 2024; 15:1208-1226.

PMID: 39376728 PMC: 11457047. DOI: 10.3762/bjnano.15.98.


Mild hyperthermia enhanced synergistic uric acid degradation and multiple ROS elimination for an effective acute gout therapy.

Zhao P, Hu H, Chen X, Jiang Q, Yu X, Cen X J Nanobiotechnology. 2024; 22(1):275.

PMID: 38778401 PMC: 11112921. DOI: 10.1186/s12951-024-02539-9.


Biomolecular interactions of ultrasmall metallic nanoparticles and nanoclusters.

Sousa A, Schuck P, Hassan S Nanoscale Adv. 2021; 3(11):2995-3027.

PMID: 34124577 PMC: 8168927. DOI: 10.1039/d1na00086a.


Ultrasmall Gold Nanoparticles Coated with Zwitterionic Glutathione Monoethyl Ester: A Model Platform for the Incorporation of Functional Peptides.

Knittel L, Zhao H, Nguyen A, Miranda A, Schuck P, Sousa A J Phys Chem B. 2020; 124(19):3892-3902.

PMID: 32352799 PMC: 8435207. DOI: 10.1021/acs.jpcb.0c01444.

References
1.
Maffre P, Brandholt S, Nienhaus K, Shang L, Parak W, Nienhaus G . Effects of surface functionalization on the adsorption of human serum albumin onto nanoparticles - a fluorescence correlation spectroscopy study. Beilstein J Nanotechnol. 2015; 5:2036-47. PMC: 4273259. DOI: 10.3762/bjnano.5.212. View

2.
Copeland R . The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov. 2015; 15(2):87-95. DOI: 10.1038/nrd.2015.18. View

3.
Fan J, de Lannoy I . Pharmacokinetics. Biochem Pharmacol. 2013; 87(1):93-120. DOI: 10.1016/j.bcp.2013.09.007. View

4.
Moss D, Siccardi M . Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. Br J Pharmacol. 2014; 171(17):3963-79. PMC: 4243971. DOI: 10.1111/bph.12604. View

5.
Peng C, Xu J, Yu M, Ning X, Huang Y, Du B . Tuning the In Vivo Transport of Anticancer Drugs Using Renal-Clearable Gold Nanoparticles. Angew Chem Int Ed Engl. 2019; 58(25):8479-8483. PMC: 6555664. DOI: 10.1002/anie.201903256. View